Levetiracetam Reduces Amyloid-β Production in the Brain
Researchers report that levetiracetam, an FDA-approved antiepileptic, reduces amyloid-β production by shifting APP processing toward the nonamyloidogenic pathway via synaptic vesicle modulation. In mice, levetiracetam prevented Aβ42 production, rescued synaptic vesicle cycling and synapse loss, and findings in Down syndrome brains support the concept of intervening before irreversible amyloid pathology.
Why it mattersLevetiracetam, an FDA-approved antiepileptic, lowers amyloid-β and warrants early prevention trial prioritization.